论文部分内容阅读
目的探析多西他塞治疗晚期非小细胞肺癌临床治疗效果。方法随机抽取本地区两家医院在2013-01-2015-12治疗的60例晚期非小细胞肺癌患者,分为两组,分别给予培美曲塞与多西他塞进行治疗,统计分析与对比两组患者的临床治疗效果。结果多西他塞组患者的临床治疗有效率与疾病控制率分别为6.7%、50%,培美曲塞组分别为13.3%、63.3%,差异无统计学意义,P>0.05。多西他塞组患者的毒副作用以皮疹、腹泻等为主,分别为36.7%、20%,培美曲塞组患者以骨髓抑制、恶心呕吐为主,分别是40%、30%,两组患者的毒副作用发生率的差异有统计学意义,P<0.05。结论多西他赛治疗晚期非小细胞肺癌临床分疗效较为理想。
Objective To investigate the clinical effect of docetaxel in the treatment of advanced non-small cell lung cancer. Methods Sixty patients with advanced non-small cell lung cancer (NSCLC) treated in two hospitals in our area from January 2013 to December 2015 were randomly divided into two groups and were treated with pemetrexed and docetaxel respectively. Statistical analysis and comparison Clinical efficacy of two groups of patients. Results The rates of clinical treatment and disease control in docetaxel group were 6.7% and 50%, respectively. Pemetrexed group was 13.3% and 63.3% respectively, with no significant difference (P> 0.05). The toxic and side effects of docetaxel were mainly rash and diarrhea, which were 36.7% and 20% respectively. The patients in pemetrexed group were mainly bone marrow suppression and nausea and vomiting, 40% and 30% The difference in the incidence of side effects among patients was statistically significant (P <0.05). Conclusion Docetaxel in the treatment of advanced non-small cell lung cancer clinical sub-effect is ideal.